https://www.latimes.com/business/technology/story/2021-03-04/this-la-company-is-building-tiny-medical-robots-to-inject-into-your-body * Business * California * Climate & Environment * Entertainment & Arts * En Espanol * Food * Housing & Homelessness * Image * Lifestyle * Obituaries * Opinion * Politics * Science * Sports * Travel * World & Nation * All Sections * _________________ * Newsletters * Photography * Podcasts * Video * _________________ * About Us + About Us + Archives + Company News + eNewspaper + For the Record + Got a Tip? + L.A. Times Careers + L.A. Times Store + News App: Apple IOS + News App: Google Play + Newsroom Directory + Reprints, Rights & Permissions + About Us + Archives + Company News + eNewspaper + For the Record + Got a Tip? + L.A. Times Careers + L.A. Times Store + News App: Apple IOS + News App: Google Play + Newsroom Directory + Reprints, Rights & Permissions * Advertising + Place an Ad + Classifieds + People on the Move + Find/Post Jobs + Local Ads Marketplace + Media Kit: Why the L.A. Times? + Hot Property Sections + Place an Open House + Sotheby's International Realty + Place an Ad + Classifieds + People on the Move + Find/Post Jobs + Local Ads Marketplace + Media Kit: Why the L.A. Times? + Hot Property Sections + Place an Open House + Sotheby's International Realty * Brand Publishing * Hot Property * Crossword & Games * L.A. Times Events * L.A. Times Store * Second Opinion * Subscriptions + Manage Subscription + EZPAY + Delivery Issue + eNewspaper + Students & Educators + Subscribe + Subscriber Terms + Manage Subscription + EZPAY + Delivery Issue + eNewspaper + Students & Educators + Subscribe + Subscriber Terms Copyright (c) 2021, Los Angeles Times | Terms of Service | Privacy Policy | CA Notice of Collection | Do Not Sell My Personal Information Sections Los Angeles Times * California * Entertainment * Sports * Food * Climate * Opinion * | * Place an Ad * Crossword * eNewspaper Show Search [ ]Search Query Submit Search Advertisement * Facebook * Twitter * Show more sharing options Share Close extra sharing options * Facebook * Twitter * LinkedIn * Email * Copy Link URLCopied! * Print Technology This L.A. start-up is building tiny injectable robots to attack tumors The helical Bionaut drug-delivery device, next to a penny for scale. The helical Bionaut drug-delivery device, next to a penny for scale. (Bionaut Labs) By Sam DeanStaff Writer March 4, 2021 5 AM PT * Facebook * Twitter * Show more sharing options Share Close extra sharing options * Facebook * Twitter * LinkedIn * Email * Copy Link URLCopied! * Print Doctors take a microscopic craft loaded with cancer-killing chemicals, inject it into the human body, and drive it to a malignant tumor to deliver its payload before making a quick exit. For most of the 55 years since "Fantastic Voyage" shrank Raquel Welch and company down to the size of a cell to zap a blood clot out of a scientist's brain, that scenario has been pure science fiction. But Bionaut Labs, a remote-control medical microrobot start-up, intends to be the first company to make it a clinical reality. Backed by $20 million in venture capital funding and building off recent advances in robotics and precision manufacturing, the Culver City company is developing a device the size of a breadcrumb that doctors can insert into the spine or skull and magnetically steer to a target to deliver a precise dose of drugs. The plan is to move to clinical trials by 2023. Advertisement Michael Shpigelmacher, Bionaut's chief executive, said that he and his co-founder, Aviad Maizels, created the company in 2016 to tackle a fundamental problem of modern medicine: getting a drug to the right place in the right dose. A close-up photo of the helical Bionaut device. A close-up photo of the helical Bionaut device. (Jon McKee Photography) Most drug delivery today is based on diffusion through the bloodstream, which requires high doses to make sure that enough of the active ingredients makes it to the target -- and often means that the rest of the body gets hit at the same time. "It's very statistical in nature and not precise," Shpigelmacher said. "We wanted to just figure out a way to get there," to the problem area, "instead of flooding a body with therapeutics." Shpigelmacher and Maizels worked together in the mid-2000s at PrimeSense, a 3-D sensing start-up that built the Xbox Kinect before being acquired by Apple in 2013, and stayed in touch as their mutual interest in the emerging field of medical microrobots grew. They zeroed in on research coming out of the Max Planck Institute for Intelligent Systems in Stuttgart, Germany, and approached the lab's leader, a scientist named Peer Fischer, about collaborating on something they could bring to market. Advertisement Fischer became Bionaut's senior scientific advisor, and the company started funding his research, before raising multiple rounds of venture capital from Upfront Ventures, Khosla Ventures and Revolution, among others, to hire a small team and begin testing the technology in living animals at its Culver City office. After four years, Shpigelmacher said, the company is ready to refine its technique and prepare for human trials. Bionaut is targeting brain stem gliomas, a type of cancer that largely affects children and young adults, as a first step for proving its tech. Brain tumors are particularly difficult to treat with current technology: Radiation and surgery can cause too much damage to the delicate tissue, and the blood-brain barrier stops most chemotherapy drugs from reaching the tumor. Being able to deliver drugs right into the tumor itself would be a significant advance. Bionaut device moving from a catheter into the subarachnoid space in a live sheep spine. Year 2020. Bionaut device moving from a catheter into the subarachnoid space in a live sheep spine. Year 2020. (Bionaut Labs) Here's how it works: A doctor inserts a handful of Bionaut devices into the spinal column through a catheter. Each device is large enough to be clearly visible on a live X-ray; the manufacturing technology exists to make the devices even smaller, but Bionaut chose to keep them close to the millimeter scale in order to make them less difficult to track and maneuver through the body. Advertisement A set of magnets positioned around the head and neck generates an external magnetic field that the doctor can control to prod the devices up the spinal column and into the affected area of the brainstem. Once they're in the right position, another magnetic signal activates a tiny plunger in each device's cargo bay, ejecting the drug. Then, the doctor can drive the devices back to where they entered the spine and remove them. Research into the science underlying Bionaut's technology began decades ago but accelerated in recent years. "There are articles from the '80s where a person takes a large screw -- I'm literally talking about a big screw that you'd put in your wall -- and controls it magnetically to move through a piece of steak," Shpigelmacher said. "That was not safe, but the concept was there." Now the field of precision manufacturing has advanced to the point that tiny medical devices can be mass-produced through a network of suppliers, in a manner similar to other consumer electronics. "It's key that we're not reinventing the wheel here," Shpigelmacher noted. Advertisement Jinxing Li, an assistant professor of biomedical engineering at Michigan State University who works on medical microrobotics, called Fischer's team at Max Planck "one of the pioneers in the technology." Li said he expects Bionaut will have a number of new competitors in the coming years, as microrobots are incorporated in an increasing number of medical procedures. Marc Miskin, an assistant professor of electrical engineering at the University of Pennsylvania who works on nanorobots, said the nervous system is particularly well suited for microrobotic interventions. "I would give them a lot of credit for figuring out a space where they can make an impact and justify how they'll be competitive with traditional pharmaceutical approaches," he said. Some minimally invasive techniques for brain surgery already rely on snaking slender endoscopes and surgical instruments up through the spinal column to reach the skull. "Getting rid of the cord is a great idea" if you can pull it off, Miskin said. "You should absolutely do it." Bionaut is also collaborating with outside researchers who are trying to develop a pharmacological treatment for Huntington's disease, which affects a set of neurons buried deep in the brain called the basal ganglia. The Bionaut system not only would allow surgeons to avoid cutting open the skull to reach the target area but also could enable them to use less damaging angles of approach through the gray matter that would be impossible without a wireless instrument. "We are freeing them physically from the straight-line requirements that they have to adhere to today," Shpigelmacher said. Advertisement The next hurdle for Bionaut is the clinical trial process. While medical devices typically go through a streamlined approval process, Bionaut's combination of new technique with drug delivery means that it must go through the full Food and Drug Administration regimen. The majority of new drugs seeking approval from the FDA fail along the way, with success rates varying widely among applications, according to a recent study out of MIT, from 33% for new vaccines for infectious diseases down to just 3.4% for experimental cancer drugs. Bionaut is targeting brainstem gliomas first in part to increase those odds. "It's a rare disease, there is no current cure, and they're delivering proven and approved chemo payloads that kill tumor cells," said Kevin Zhang, a partner at Upfront Ventures who led the fund's investment in Bionaut. Treatments targeting rare conditions can apply for "orphan" status with the FDA, which provides tax benefits and streamlines the regulatory process. "The best way to improve your odds, other than having a good solution," Zhang said, "is to pick the right problem to go after with high unmet needs." If the glioma treatment makes it through clinical trials, the plan is to expand the technology to other central nervous system conditions and other areas that are difficult to target with drugs, such as inside the eye. Moving into the rest of the body is further out on the horizon. But putting serious money behind the approach to bring it out from the lab and into operating rooms is the first step. When Shpigelmacher first approached investors about the idea that would become Bionaut, most pushed back, urging him to wait for academic researchers to refine the science. To Shpigelmacher, commercialization was the way to "get to patients sooner than it would have otherwise," he said. "Not at the pace of academia." --------------------------------------------------------------------- TechnologyBusiness Newsletter Your guide to our new economic reality. Get our free business newsletter for insights and tips for getting by. Enter email address [ ] Sign Me Up You may occasionally receive promotional content from the Los Angeles Times. [] Sam Dean Follow Us * twitter * instagram * email * facebook Sam Dean is a business reporter for the Los Angeles Times covering the technology industry in Southern California. He has previously worked as a feature writer for a number of publications including Newsweek, the Verge, 538 and Lucky Peach. Show Comments More From the Los Angeles Times * Entertainment & Arts The tech behind 'Fortnite' and 'The Mandalorian' is now driving ... Shakespeare? Rehearsal photos from the Royal Shakespeare Co.'s production of 'Dream,' a 50-minute interactive work of theater that brings live actors to what is essentially a video game space. Entertainment & Arts The tech behind 'Fortnite' and 'The Mandalorian' is now driving ... Shakespeare? The Royal Shakespeare Company's 'Dream' brings live actors to online audiences, who can interact with the play like they would a video game. * Technology Facebook to lift political ad ban FILE - This March 29, 2018 file photo, shows the logo for social media giant Facebook at the Nasdaq MarketSite in New York's Times Square. With just two months left until the U.S. presidential election, Facebook says it is taking additional steps to encourage voting, minimize misinformation and reduce the likelihood of post-election "civil unrest." The company said Thursday, Sept. 3, 2020, it will restrict new political ads in the week before the election and remove posts that convey misinformation about COVID-19 and voting. (AP Photo/Richard Drew, File) Technology Facebook to lift political ad ban After halting all new political ads in the U.S. in the week leading up to November's general election, a move aimed at averting misinformation and unrest, Facebook is set to resume allowing them. * Technology Google vows no new user tracking in Chrome ad data changes FILE - This March 19, 2018 file photo shows the Google app on an iPad in Baltimore. Google says it won't develop new ways to follow individual users across the internet after it phases out existing ad tracking technology from Chrome browsers in an upcoming overhaul aimed at tightening up privacy. (AP Photo/ Patrick Semansky, File) Technology Google vows no new user tracking in Chrome ad data changes The digital giant has been working on proposals to remove from Chrome so-called third-party cookies -- snippets of code used by a website's advertisers to record browsing history. * Technology Intel is told to pay $2.18 billion after losing a patent trial The Intel logo is displayed outside the entrance of Intel headquarters in Santa Clara, Calif., Wednesday, Jan. 12, 2011. Intel Corp., releases quarterly financial results Thursday, Jan. 13, after the market close. (AP Photo/Paul Sakuma) Technology Intel is told to pay $2.18 billion after losing a patent trial After losing a patent-infringement trial over technology related to chip-making, Intel was ordered to pay VSLI Technology one of the largest patent-damages awards in U.S. history. Advertisement Latest Technology * Entertainment & Arts How the creator of 'Final Fantasy' challenges himself: A game made with 150 dioramas "Fantasian" is a role-playing game with headed soon to Apple Arcade. The game is set amid 150 hand-crafted diorama enviornments. Entertainment & Arts How the creator of 'Final Fantasy' challenges himself: A game made with 150 dioramas Game designer Hironobu Sakaguchi is thinking big, but the look is small for 'Fantasian,' coming later this year exclusively to Apple Arcade game service. * Business Column: Privacy or planet -- the tough choice of doing away with paper receipts Laurie Palmer, of Portland, Ore., checks her sales receipt after checking out at Walmart. Business Column: Privacy or planet -- the tough choice of doing away with paper receipts Switching to digital-only receipts for transactions would be good for the environment. But it would be another nail in the coffin of your privacy. * Business How the debate over holding internet platforms accountable is changing under Biden Top row, Facebook CEO Mark Zuckerberg, right, Amazon CEO Jeff Bezos, second from right, and bottom row Google CEO Sundar Pichai, left, and Apple CEO Tim Cook, second from left are sworn in remotely during a House Judiciary subcommittee on antitrust on Capitol Hill on Wednesday, July 29, 2020, in Washington. (Mandel Ngan/Pool via AP) Business How the debate over holding internet platforms accountable is changing under Biden Section 230 has been a 'brick wall' for anyone seeking to sue internet companies over user-generated content, but bills and legal strategies under consideration could represent an opportunity to change that. * Technology U.S. signals it will proceed with proposed rule aimed at curbing China tech threats Wilbur Ross, the billionaire financier selected to be Commerce secretary, speaks at Senate confirmation hearing. Technology U.S. signals it will proceed with proposed rule aimed at curbing China tech threats Biden plans to implement a rule authored under Trump that gives the Commerce Department authority to ban transactions involving 'foreign adversaries.' * Technology Bitcoin heads for worst weekly drop since March amid sell-off Elon Musk, chairman and CEO at Tesla and chairman of SpaceX, inhales what he said was marijuana on a live YouTube webcast on Sept. 6. Technology Bitcoin heads for worst weekly drop since March amid sell-off Bitcoin's rough patch comes amid increased volatility in global markets, as a surge in bond yields heralds growing expectations that growth and inflation are moving higher. Advertisement Advertisement Advertisement Advertisement Advertisement Advertisement Advertisement Advertisement Advertisement Los Angeles Times A California Times publication Subscribe for unlimited access Follow Us * twitter * instagram * youtube * facebook * + eNewspaper + Coupons + Find/Post Jobs + Place an Ad + Media Kit: Why the L. A. Times? + Bestcovery * + Crossword + Sudoku + Obituaries + Recipes + Smart Speakers + Wine Club * + About/Contact + For the Record + L.A. Times Careers + Manage Subscription + Reprints and Permissions + Site Map Copyright (c) 2021, Los Angeles Times | Terms of Service | Privacy Policy | CA Notice of Collection | Do Not Sell My Personal Information